IC
PBLA

Ikarian Capital’s Panbela Therapeutics, Inc. Common Stock PBLA Stock Holding History

Ikarian Capital’s Portfolio PBLA Stock Details PBLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-15
Closed -$750K – 229
2022
Q1 		$750K Buy
15
+1
+7% +$46.1K 0.1% 110
2021
Q4 		$592K Hold
14
– – 0.09% 120
2021
Q3 		$734K Hold
14
– – 0.05% 172
2021
Q2 		$976K Hold
14
– – 0.08% 162
2021
Q1 		$1.36M Buy
+14
New +$1.58M 0.05% 226

Other funds holding PBLA

BAMG
Brand Asset Management Group Chesterfield, Missouri $452M AUM 25.97% 1-Year Est. Return
BSW
Buckingham Strategic Wealth Clayton, Missouri $9.66B AUM 15.76% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
E
Ergoteles New York $68.2M AUM 36.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Ikarian Capital's PBLA Position: Q2 2022 in Review

Ikarian Capital sold out of Panbela Therapeutics, Inc. Common Stock (PBLA) in Q2 2022, closing a stake of 15 shares — an estimated $750K sold.

Ikarian Capital first reported a position in PBLA in Q1 2021 and held it in 5 quarters. The position peaked at $1.36M in Q1 2021. 7 funds tracked by Wall St. Rank hold PBLA as of Q2 2022.

  • Ikarian Capital reported no remaining Panbela Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Ikarian Capital sold 15 Panbela Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $750K.
  • Ikarian Capital first reported a position in Panbela Therapeutics, Inc. Common Stock in Q1 2021 and held it in 5 quarters.
  • Ikarian Capital's Panbela Therapeutics, Inc. Common Stock position peaked at $1.36M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Panbela Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Ikarian Capital's 13F filing for Q2 2022, filed 12 Aug 2022.